Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients

Thorax

Volumn 51, Issue 3, 1996, Pages 262-266

  Clark, D J ^a   Grove, A ^a   Cargill, R I ^a   Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adrenal suppression; Asthma; Budesonide; Fluticasone propionate; Inhaled corticosteroids

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; PLACEBO;

ADRENAL SUPPRESSION; ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0030008193     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.3.262     Document Type: Article

References (18)

1. British Thoracic Society. Guidelines for management of asthma: a summary. BMJ 1993;306:776-82.
2. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149(Suppl):A212.
3. Anderson N, Klint S, Randwall G, Wiren JE. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay. Thorax 1994;49:422P.
4. Phillips GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990;84(Suppl A):19-23.
5. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-10.
6. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84(Suppl A):25-9.
7. Ryrfedlt A, Anderson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63(Suppl 122):86-95.
8. Melchor R, Biddescome MF, Mak VHF, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993;48:506-11.
9. Grove A, Allam C, McFarlane LC, McPhate G, Jackson CM, Lipworth BJ. A comparison of systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994;38:527-32.
10. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-43.
11. Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994;38:521-5.
12. Borgstrom L, Bondessan E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbohaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994;7:69-73.
13. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
14. Boe J, Bakke P, Rodolen T, Skovlund E, Gulsvik A. High dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J 1994;7:2179-84.
15. Fabbri L, Burge PS, Croonenburgh L, Warlies F, Weeke B, Ciacca A, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48:817-23.
16. Ayres JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;8: 579-86.
17. Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Therap 1993;58:173-209.
18. Bain BM, Harrison G, Jenkins KD, Pateman AJ, Shenoy EVB. A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. J Pharmaceut Biomed Analysis 1993;11:557-61.